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Analgesic efficacy and side effects of oral tramadol and morphine
administered orally in the treatment of cancer pain
Wojciech Leppert
A i m s  o f  t h e  s t u d y. To assess the analgesic efficacy and side effects of tramadol and equianalgesic doses of morphine and
to assess the quality of life (QL) in patients suffering from cancer pain and to establish equianalgesic doses of oral tramadol
and morphine.
Pa t i e n t s  a n d  m e t h o d s. Fourty opioid-naive patients with moderate, strong or very strong cancer pain (verbal scale) or
at least 45 mm on VAS scale, were treated with tramadol (20 patients) or morphine (20 patients). During the first 7 days the
pain was stabilised by the use of immediate release forms of tramadol (drops, capsules) or morphine (water solution). After
7 days, if a satisfactory pain relief was achieved and appropriate daily doses were applied (tramadol 150-600 mg, morphine
20-200 mg) patients were switched to controlled release forms of tramadol – Tramal Long (Retard) tablets – or sustained re-
lease morphine (MST Continus tablets or M-eslon capsules) for 28 days. QL was assessed by QLQ C 30 questionnaire. Pa-
in intensity was appraised by VAS and verbal scale, side effects by verbal scale.
R e s u l t s. The duration of treatment was 3-310 (mean 87.15±78.23) days for Tramal Retard and 5-502 (mean
100.05±102.67) days for morphine MST Continus and M-eslon. Daily doses were as follows: 200- 600 (mean 322.22±116.60)
mg for tramadol and 20-270 (123.5±78.15) mg for morphine. Satisfactory analgesia was achieved in both groups. However,
in patients with neuropathic pain better analgesic effect was noted in the morphine group (significant difference in VAS sca-
le after first week of the treatment). 80% of patients in both groups preferred the treatment with controlled release forms of tra-
madol and morphine. The treatment was well tolerated, 17 patients in tramadol group and 18 in morphine group completed
the study. More side effects were noted in morphine group, however significant differences appeared only in drowsiness, dif-
ficulties in passing urine, sweating and dizziness intensity. QL results revealed better global QL and less fatigue after 35 days
of the tramadol treatment.
C o n c l u s i o n s. Tramadol and equianalgesic doses of morphine (up to 270 mg/day) in immediate and controlled release
forms are effective in the treatment of different types of moderate and severe cancer pain. Tramadol is less effective in patients
with neuropathic pain. Both drugs can be safely used at home. Better global QL and less fatigue was observed after 35 days
of the tramadol treatment. Tramadol is recommended in patients with moderate pain (VAS 30-54 mm) and morphine in pa-
tients with severe and very severe pain (VAS >54 mm). Equianalgesic doses of tramadol and morphine administered orally
are 4:1.
Ocena przydatnoÊci analgetycznej i objawów ubocznych tramadolu i morfiny,
podawanych drogà doustnà, w leczeniu bólu nowotworowego
C e l e  b a d a n i a. Ocena analgezji, objawów ubocznych i jakoÊci ˝ycia (J˚) podczas leczenia tramadolem i ekwiwalentny-
mi dawkami morfiny, u chorych z bólem nowotworowym oraz ustalenie równowa˝nych dawek obu leków, podawanych
drogà doustnà.
B a d a n i  c h o r z y  i m e t o d y. 40 chorym z bólem nowotworowym o umiarkowanym, silnym lub bardzo silnym nat´˝eniu
wg skali s∏ownej lub przynajmniej 45 mm wg skali VAS, którzy uprzednio nie byli leczeni analgetykami opioidowymi, w ramach
otwartego, randomizowanego, równoleg∏ego, prospektywnego badania, podawano tramadol (20 chorych) lub morfin´ (20 cho-
rych). Przez pierwsze 7 dni chorzy otrzymywali tramadol (krople lub kapsu∏ki) lub morfin´ (roztwór wodny) o natychmia-
stowym uwalnianiu, po uzyskaniu satysfakcjonujàcej kontroli bólu i odpowiedniej dawki dobowej badanego leku (tramadol
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The aim of the study was:
– to compare analgesic efficacy and side effects of trama-
dol and morphine, administered orally, in the treat-
ment of different types of cancer pain in patients thre-
ated by home palliative care team,
– to assess analgesia, side effects and preference of the
type of treatment expressed by patients receiving treat-
ment with immediate release and controlled release
preparations of tramadol and morphine,
– to establish the impact of type of the analgesic (trama-
dol or morphine) on patients' quality of life (QL),
– to establish equianalgesic oral doses of tramadol and
morphine.
Patients and methods
An open, randomised prospective study was performed,
with the participation of 40 patients staying at home, suf-
fering from cancer pain of moderate, strong and very
strong intensity, according to verbal scale and over 45
mm on VAS scale, demanding opioid analgesics admini-
stration. Patients were randomly assigned to one of the
two groups:
– receiving tramadol.
– receiving morphine.
All patients gave their written consent for the participa-
tion in this trial. The Regional Ethics Committee at the
Karol Marcinkowski Medical University approved con-
ducting of the trial. The list of random assignment to one
of the two groups was prepared by Statistical Depart-
ment. Patients eligible for the study had to fulfil the follo-
wing criteria:
– at least 18 years old,
– diagnosis of cancer,
– opioid – naive patients,
– oral route of tramadol or morphine administration,
– moderate, strong or very strong pain intensity accor-
ding to verbal scale and at least 45 mm on the VAS sca-
le that demanded opioid analgesic administration,
– overall state of the patients that allowed to expect
completing the trial (total time of the study was 35
days),
– patients able to communicate effectively in order to
fulfil EORTC QLQ C 30 questionnaire.
Patients with primary or metastatic brain tumours
(pain caused by raised intracranial pressure) and patients
with kidney insufficiency (creatinine level in serum >1.5
mg%) were excluded from the study. In statistical analy-
ses significant differences were established on the level of
p<0.05.
Using Mann-Whitney test no significant differences
were found in the number of patients, gender, height,
weight, age, activity (PS – performance status: ECOG
and Karnofsky scale) between patients receiving tramadol
and morphine.
In both groups of patients different diagnoses of pri-
mary tumours were found. Majority of patients in both
tramadol and morphine group had primary tumours loca-
lised in alimentary system (7 and 4 patients), lung (5 in
both groups), urinary system (3 and 4), other sites (5 and
7 patients respectively).
In both groups of patients different types of cancer
pain occurred: visceral, bone, neuropathic and somatic
from soft tissues. In the group treated with tramadol one
type of pain appeared in 14 patients, two types of pain oc-
curred in 6 patients; in the group treated with morphine
in 15 and 5 patients respectively. Using Gauss test no si-
gnificant differences were found in the frequency of visce-
150-600 mg, morfina 20-200 mg), przez kolejne 28 dni chorym podawano tramadol (tabletki Tramal Retard) lub morfin´ (ta-
bletki MST Continus bàdê kapsu∏ki M-eslon) o kontrolowanym uwalnianiu. Ocen´ J˚ przeprowadzano przy u˝yciu kwestio-
nariusza EORTC QLQ C 30. Nat´˝enie bólu oceniano wg skali VAS i s∏ownej, nat´˝enie objawów ubocznych wg skali
s∏ownej.
W y n i k i. Czas leczenia Tramalem Retard wynosi∏ 3-310 dni (Êrednio 87,15±78,23 dni), morfinà MST Continus i M-eslon
5-502 dni (Êrednio 100,05±102,67 dni). Zakres dobowych dawek stosowanych leków wynosi∏ dla tramadolu 200-600 mg (Êred-
nia 322,22 mg ± 116,60), dla morfiny 20-270 mg (Êrednia 123,5 mg ± 78,15). W obu grupach chorych uzyskano korzystne
efekty przeciwbólowe. W grupie chorych z bólem neuropatycznym nat´˝enie bólu by∏o mniejsze podczas leczenia morfinà (ró˝-
nica statystycznie znamienna po 7 dniach leczenia). Wi´kszoÊç leczonych chorych (80% w obu grupach) preferowa∏a lecze-
nie preparatami tramadolu i morfiny o kontrolowanym uwalnianiu. Leczenie by∏o dobrze tolerowane, badanie ukoƒczy∏o 17
chorych leczonych tramadolem i 18 otrzymujàcych morfin´. Objawy uboczne wyst´powa∏y cz´Êciej w grupie chorych leczonych
morfinà, choç ró˝nice znamienne obserwowano tylko w nat´˝eniu sennoÊci, trudnoÊci w oddawaniu moczu, zawrotów g∏owy
i pocenia. Badania J˚ wykaza∏y lepszà ogólnà J˚ i mniejsze nat´˝enie zm´czenia po 35 dniach leczenia tramadolem.
W n i o s k i. Stosowanie drogà doustnà tramadolu i ekwiwalentnych dawek morfiny (nie przekraczajàcych 270 mg/dob´), o na-
tychmiastowym i kontrolowanym uwalnianiu, stanowi skuteczny sposób analgezji u chorych z ró˝nymi rodzajami bólu nowo-
tworowego o umiarkowanym i silnym nat´˝eniu. Tramadol jest mniej skuteczny w leczeniu bólu neuropatycznego. Oba leki mo-
gà byç bezpiecznie stosowane w warunkach domowych. Podawanie tramadolu zwiàzane jest z lepszà ogólnà J˚ i mniejszym
nasileniem zm´czenia po 35 dniach leczenia. Tramadol jest zalecany u chorych z bólem o umiarkowanym nat´˝eniu (VAS 30-
-54 mm), a morfina u chorych z bólem o silnym i bardzo silnym nat´˝eniu (VAS >54 mm). Ekwiwalentne dawki tramado-
lu i morfiny, podawane drogà doustnà wynoszà 4:1.
Key words: analgesia, morphine, pain, tramadol
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ral, bone, neuropathic and somatic from soft tissues pain
between patients' groups.
Pain was measured by VAS and 5-step verbal scale: 0
– no pain, 1 – weak, 2 – moderate, 3 – strong, 4 – very
strong pain. Patients assessed analgesic effects of admini-
stered opioid according to 5 – step verbal scale: 1 – very
good, 2 – good, 3 – moderate, 4 – weak, 5 – no effect.
Before starting the treatment patients treated with
tramadol suffered from moderate (2 patients), strong (14
patients) and very strong (4 patients) pain intensity (ver-
bal scale), according to VAS pain intensity was 47-99 mm
(mean 82.05±16.01). Patients treated with morphine had
similar pain intensity: according to verbal scale 1 patient
had moderate pain, strong pain – 12 patients, very strong
pain – 7 patients; using VAS scale pain intensity was 50-
-100 mm (mean 78.50±14.08). During first 7 days of the
trial patients received tramadol or morphine in imme-
diate release preparations (tramadol in drops or capsules,
morphine in 0.5 % water solution). Both analgesics were
administered every 4 hours, with a break during the night.
The dose before sleep was increased by 50%. Starting
doses were as follows: for tramadol 25-50 mg, for morphi-
ne 5 mg. Doses were adjusted depending on analgesia
and side effects, usually increased by 50%.
During first 3 days of therapy in both groups of pa-
tients metoclopramide 10 mg t. i. d. was given as the pro-
phylaxis of nausea and vomiting. After 3 days the treat-
ment was stopped, but if nausea or vomiting appeared
the therapy was continued or restarted.
After 7 days of the therapy with immediate release
forms of opioids, if satisfactory pain control was achieved
(VAS <50 mm or in verbal scale moderate, weak or
no pain), patients were treated with controlled release
formulations (in tramadol group – Tramal Retard
(Long) 100, 150 and 200 mg tablets, in morphine group –
MST Continus 10, 30, 60, 100 mg tablets or M – eslon 10,
30, 60, 100 mg capsules). To enter the second part of the
study, patients had to receive daily doses of tramadol of
150-600 mg and morphine of 20-200 mg. Treatment with
controlled release formulation lasted 28 days, total trial ti-
me was 35 days. During treatment with controlled release
preparations, in case of breakthrough pain occur patients
received tramadol and morphine in immediate release
formulations. The rescue doses were 10-25% of the daily
dose of the controlled release form of analgesic used re-
gularly by the patient and usually were equal to the pre-
vious single immediate release doses of the drug during
first 7 days of the treatment.
On the 7th day of the treatment with immediate re-
lease formulations of opioids (7th day of the trial) and
also on the 14th and 28th day of the treatment with con-
trolled release formulations of opioids (on 21st and 35th
day of the trial respectively), patients filled EORTC QLQ
C 30 questionnaire. At the same time, assessment of pain
(verbal scale), analgesic effects of administered opioid
(performed by patients), side effects of the treatment,
performance status, heart rate, blood pressure, consump-
tion of rescue analgesics used in case of breakthrough
pain occurred were performed. Patients assessed pain in-
tensity on the VAS scale once a week. On the 28th day of
the treatment with controlled release opioids (35th day
of the trial) patients assessed the therapy and their prefe-
rence of type of the treatment (with immediate or control-
led release formulation) which would be continued during
follow up. Patients who preferred therapy with controlled
release formulations of tramadol or morphine could con-
tinue this type of treatment for unlimited time.
Results
Among 20 patients treated with Tramal Retard (Long)
the drug was administered through all period of the trial
(28 days) in 17 (85%) patients. 3 patients (15%) disconti-
nued treatment: 1 patient – after 3 days – because of side
– effects, (she continued treatment with tramadol drops);
1 patient had unsatisfactory analgesic effect of Tramal
Retard, (after 7 days of therapy she returned to the treat-
ment with tramadol drops and died on 34th day of the
trial), in the third patient, after 21 days of Tramal Long
administration it was necessary to change the oral for
subcutaneous route; due to dyspnoea and insufficient
analgesia Tramal Retard was substituted by morphine,
she died on 30th day of the study. All patients who com-
pleted the study continued treatment with Tramal Long
during follow up.
Of 20 patients treated with controlled release mor-
phine 11 received MST Continus tablets, 9 with M-eslon
capsules. 18 (90%) patients completed the 28 days of the
therapy, 2 patients discontinued the treatment: 1 patient
died on 25th day of the therapy with M-eslon (32nd day of
the trial), the second patient stopped M-eslon therapy
(dose 80 mg/day) on the 5th day because of side effects
which disappeared after continuation of the treatment
with equivalent dose (75 mg/day) of morphine water solu-
tion. Similarly as in the tramadol group all other patients
continued treatment with controlled release morphine
preparations after completing entire study period during
follow up. All patients' data was included in statistical
analysis of the results (also patients who received imme-
diate release preparations and who died during the study
period).
The time of the treatment with Tramal Retard
(Long) was 3-310 (mean 87.15±78.23) days, with mor-
phine MST Continus and M-eslon 5-502 (mean
100.05±102.67) days. The daily doses of analgesics was
200-600 (mean 322.22±116.60) mg for tramadol and 20-
-270 (mean 123.5 mg±78.15) mg for morphine.
The mean rescue doses of the studied analgesics
used in case of breakthrough pain during 28 days of the
treatment with controlled release preparations were
528.125 mg±845.98 (range 0-2800 mg) for tramadol and
235.98 mg±285.65 (range 0-1680 mg) for morphine.
In both groups of patients before and during the tre-
atment (after 1st, 3rd and 5th week of the treatment) no si-
gnificant differences in circulatory system parameters
such as heart rate, systolic and diastolic blood pressure
and performance status (both ECOG and Karnofsky sca-
le) were observed.
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A n a l g e s i c  e f f e c t s
Beneficial, comparable results of analgesic effects have
been achieved during the treatment with tramadol and
morphine. Results in patients treated with tramadol and
morphine before commencing the therapy, during admi-
nistration of immediate (after 1st week of the therapy)
and controlled release formulations (after 2nd, 3rd, 4th
and 5th week of the treatment) were compared. Compari-
son of mean values and standard deviation (SD) of pain
intensity (VAS scale) is shown in Table I.
Using Mann – Whitney test no significant differences
were found in pain intensity (VAS scale), between pa-
tients treated with tramadol and morphine, before com-
mencing and during the treatment with immediate release
(after first week) and controlled release (after 2nd, 3rd,
4th and 5th week of the treatment). Using Friedman's test
significant differences were found in pain intensity befo-
re starting and after 1st, 2nd, 3rd, 4th and 5th week of the
treatment in both groups. Comparison of pain measure-
ments performed after the 1st week didn't reveal differen-
ces.
In both groups of patients pain was assessed by ver-
bal scale before and after the 1st, 3rd, 5th week of the treat-
ment. Using Friedman's test significant differences were
found between pain intensity before starting the treat-
ment and in consecutive measurements after 1st, 3rd and
5th week of the therapy in both groups of patients. Howe-
ver using Mann – Whitney's test no significant differences
were found between patients treated with tramadol and
morphine before commencing and after 1st, 3rd and 5th
week of the treatment.
Results of pain treatment in patients treated with
tramadol and morphine in different types of pain: visceral,
bone, neuropathic and somatic from soft tissues are
shown in Table II. Using Mann – Whitney test no signifi-
cant differences have been found between patients treated
with tramadol and morphine, before starting and during
therapy in patients with visceral and somatic pain from
soft tissues. In patients with bone pain its intensity before
Tab. I. Pain intensity – VAS scale (mean ± SD)
Pain Tramadol Morphine Statistical
intensity treatment treatment significance
Before starting the treatment 82.05 ± 16.01 78.50 ± 14.08 NS
After 1 week of the treatment 39.00 ± 24.51 30.50 ± 21.35 NS
After 2 weeks of the treatment 40.10 ± 20.50 34.85 ± 25.16 NS
After 3 weeks of the treatment 38.40 ± 19.35 36.10 ± 24.53 NS
After 4 weeks of the treatment 35.70 ± 21.22 38.05 ± 20.20 NS
After 5 weeks of the treatment 36.83 ± 20.98 39.47 ± 22.49 NS
Tab. II. Results of tramadol and morphine treatment in different types of pain – VAS scale (mean ± SD)
Type of Pain Time of the treatment Tramadol Morphine Statistical
treatment treatment significance
Visceral 0 80.64 ± 18.46 79.00 ± 13.25 NS
1 34.45 ± 22.45 24.92 ± 19.38 NS
2 34.00 ± 16.74 36.33 ± 21.17 NS
3 32.54 ± 16.47 36.75 ± 22.59 NS
4 33.36 ± 23.82 37.08 ± 19.51 NS
5 30.10 ± 19.74 32.45 ± 22.66 NS
Bone 0 89.43 ± 12.50 72.20 ± 10.38 p<0.05
1 40.86 ± 28.26 26.80 ± 27.03 NS
2 47.14 ± 22.99 31.80 ± 24.86 NS
3 36.00 ± 25.11 37.20 ± 20.30 NS
4 32.00 ± 15.98 35.20 ± 16.72 NS
5 38.50 ± 16.23 39.80 ± 18.30 NS
Neuro- 0 83.80 ± 14.27 78.00 ± 13.64 NS
Pathic 1 57.00 ± 13.82 19.25 ± 16.28 p<0.05
2 60.00 ± 24.38 43.00 ± 15.83 NS
3 57.40 ± 22.03 46.50 ± 15.85 NS
4 49.40 ± 21.87 43.50 ± 15.37 NS
5 55.60 ± 23.07 45.50 ± 20.60 NS
Somatic from 0 72.67 ± 22.28 78.00 ± 13.64 NS
soft tissues 1 40.33 ± 24.92 19.25 ± 16.28 NS
2 42.00 ± 15.39 34.00 ± 15.85 NS
3 37.33 ± 18.52 39.50 ± 31.01 NS
4 41.67 ± 22.72 40.50 ± 15.37 NS
5 36.00 ± 28.28 42.20 ± 30.60 NS
Time of the treatment: 0 – before starting the therapy, 1 – after 1 week of the treatment, 2 – after 2 weeks, 3 – after 3 weeks, 4 – after 4 weeks,
5 – after 5 weeks of the treatment
261
therapy was greater in the tramadol group (significant
difference), during therapy no significant differences we-
re found between both groups. In patients with neuro-
pathic pain, after first week of therapy significant differen-
ce appeared in morphine group (less pain intensity), apart
from that in this type of pain no significant differences be-
fore and during the treatment were found. In all types
of pain significant decrease in pain intensity was noticed
before and during treatment with tramadol and morphine.
Patients assessed analgesic efficacy of tramadol or
morphine (verbal scale) three times (after 1, 3 and 5 we-
eks). Using Mann – Whitney's test no significant diffe-
rences were observed between tramadol and morphine
treatment with immediate (after 1st week of the treat-
ment) and controlled release preparations (after 3rd and
5th week of the therapy).
S i d e  e f f e c t s
In Tramal Retard group 3 patients (15%) discontinued
the treatment; 2 patients of this group died during the
study. 1 patient after 3 days (on 10th day of the study) di-
scontinued Tramal Retard (daily dose 500 mg), because of
side effects: intense sweating, anxiety, palpitations; she
returned to the treatment with tramadol drops at the sa-
me dose which was much better tolerated and she conti-
nued the treatment until death. The second patient stop-
ped treatment with Tramal Retard on 7th day (14th day of
the study) in the dose of 200 mg/day, because analgesia
was worse; she also returned to tramadol drops at the
same dose with better pain control. From the 33rd day of
the study tramadol was administered subcutaneously due
to general deterioration and inability to swallow the drug.
She died on the 34th day of the trial. The third patient
after 21 days of the treatment (on 28th day of the study)
with Tramal Retard in dose 400 mg/day, suffered from
general deterioration, dyspnoea, confusion and increase in
pain intensity. Tramal Retard was discontinued and mor-
phine 40 mg/day was started subcutaneously, effective
pain control and relief of dyspnoea were achieved; agita-
tion was eliminated by midazolam in the dose 20 mg/day.
After 2 days (on the 30th day of the trial) the patient died.
In the group treated with morphine, 2 patients
(10%) didn't complete the study. 1 patient received M-
-eslon (80 mg/day), after 5 days of the treatment (on the
12th day of the study) she discontinued therapy due to
increasing side effects: malaise, shaking of legs, anxiety
and worse analgesic effect. She returned to the treatment
with morphine solution (75 mg/day) with better analgesia;
side effects gradually disappeared. The second patient
was treated with M-eslon (80 mg/day) until death (he
died on the 25th day of the treatment, 33rd day of the
trial) with good analgesic effect.
Side effects were the cause of discontinuation the
therapy in 1 patient treated with Tramal Retard and in 1
patient treated with morphine M-eslon. In remaining pa-
tients side effects didn't cause cessation of treatment with
Tramal Long or MST Continus and M-eslon. Respiratory
depression, allergy or other serious adverse events con-
nected with tramadol or morphine administration were
not observed.
The most frequent side effects in both groups of pa-
tients were dry mouth, constipation and drowsiness, espe-
cially in morphine group. Laxatives were used in 12 (60%)
patients treated with tramadol (3 patients received 2 laxa-
tives, other received 1 laxative) and 14 (70%) patients
treated with morphine (in this group 5 patients received 2,
3 or 4 laxatives).
The most rare side effects in both groups were men-
tal disorders (confusion) and vomiting. All symptoms ap-
peared more frequently in morphine group, however si-
gnificant differences (using Mann – Whitney's test) were
observed only in drowsiness (after 1st, 3rd and 5th week of
the treatment), difficulties in passing urine and dizziness
(after 3rd week of the treatment) and sweating (after 1st
week of therapy).
Fo l l o w  u p
Before summing up results of the study 5 (25%) patients
continued the treatment with Tramal Retard; 3 (15%)
discontinued the treatment during the trial. From rema-
ining 12 (60%) patients who completed the study 8 died.
In this group 2 patients received tramadol until the end of
life by subcutaneous route, in the remaining 6 patients
due to increase in pain intensity while on Tramadol Re-
tard (5 patients) and due to severe dyspnoea (1 patient) in
spite of good analgesia it was necessary to substitute tra-
madol by morphine.
Until working out results of this study the treatment
with controlled release morphine formulation was conti-
nued by 4 (20%) patients: 2 received M-eslon capsules, 2
MST Continus tablets. The remaining 14 (70%) patients
died after completing the study; 2 (10%) discontinued
the treatment with controlled release morphine during
the trial.
From the group of 14 patients who died after com-
pleting the trial 3 (21%) patients received controlled rele-
ase preparations of morphine until the end if life (MST
Continus Tablets 2, M-eslon capsules 1), 1 (7%) patient
discontinued treatment with MST Continus tablets be-
cause pain has disappeared (patient did not demand any
analgesics), 10 (72%) patients received morphine subcu-
taneously: 6 because of inability to swallow for short pe-
riod of time during agony, 3 due to nausea and vomiting,
1 patient demanded continuous, subcutaneous infusion of
morphine with ketamine due to severe neuropathic pain.
P r e f e r e n c e  o f  t h e  t r e a t m e n t
In tramadol group 16 (80%) patients assessed Tramal
Retard treatment higher, 1 (5%) patient assessed treat-
ment with drops and retard tablets as equally effective, 2
(10%) patients who discontinued the treatment with Tra-
mal Long preferred tramadol in drops.
In morphine group 16 (80%) patients assessed MST
Continus and M-eslon higher than morphine in water so-
lution, 2 (10%) patients assessed both types of treatment
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as equally effective, 1 (5%) patient who discontinued tre-
atment with M-eslon preferred morphine in water solu-
tion, 1 (5%) patient didn't express preference.
Q u a l i t y  o f  l i f e  a s s e s s m e n t
QL assessment was performed using EORTC QLQ C 30
questionnaire in both groups of patients on 7th, 21st and
35th day of the trial.
There were no differences in the results in the first
QL measurement, both in functioning and symptoms sca-
les between patients treated with tramadol and morphine.
Similar results occurred in the second QL measurement
apart from financial impact which was bigger in patients
treated with morphine but the difference was only near si-
gnificant (p=0.054).
In the third QL measurement significant difference
appeared (p=0.001) in the emotional functioning, it was
better in morphine group. In financial impact significant
difference was noted (p=0.026), patients treated with
morphine had more financial problems. No significant
differences were observed in other functioning and all
symptom scales.
Two factorial analysis of variance of functioning sca-
les was performed. Functioning scales of EORTC QLQ
C 30 were dependent variables, type of the treatment
(tramadol or morphine) and time of QL measurement
were independent variables. Main effects were patients'
group (treated with tramadol or morphine), time of QL
measurement and their interaction. In case significant
difference occurred in main effects, finding in which me-
asurements differences were significant was based on
LSD (least difference) test.
In physical, cognitive and social functioning no si-
gnificant differences were found in any of the explored
main effects. In role functioning (work) differences were
observed depending on period of the treatment. LSD test
revealed significant differences between 1 and 3 measure-
ment (tramadol group), between 1 and 3, 2 and 3 me-
asurement (morphine group); between 1 (tramadol), 2
and 3 measurement (morphine) also between 2 (trama-
dol) and 3 measurement (morphine).
In emotional functioning significant difference were
found in all 3 main effects: type of the treatment, time of
the QL measurement and their interaction. In tramadol
group significant differences were found between 1 and 3,
between 2 and 3 QL measurement; also between 1 (tra-
madol) and 1, 3 measurement (morphine), between 2
(tramadol), and 1, 3 measurement (morphine), between 3
(tramadol) and 1, 2, 3 measurements (morphine).
In global QL significant difference was found in inte-
raction between patients' groups and time of QL measu-
rement. LSD test revealed significant difference between
3 measurement in patients treated with tramadol and
morphine – global QL was higher in tramadol group
(p=0.05 – Fig. 1).
Two factorial analysis of variance of symptom scales
was performed. Symptom scales of EORTC QLQ C 30
were dependent variables, type of the treatment (trama-
dol or morphine) and time of QL measurement were in-
dependent variables.
In most symptom scales (nausea and vomiting, pain)
and single items (dyspnoea, sleep disturbance, constipa-
tion, diarrhoea) no significant differences were found.
Using two factorial analysis of variance significant diffe-
rences in fatigue and two items: appetite loss and financial
impact were detected.
In fatigue and appetite loss scales an interaction be-
tween patients' groups and time of QL measurement was
found. In fatigue scale significant difference was found be-
tween 1 and 3 measurement (tramadol), between 2 and 3
measurement (morphine), between 2 measurement (tra-
madol) and 3 (morphine), between 3 measurement (tra-
madol) and 1 and 3 (morphine). The intensity of fatigue
was bigger in all three measurements in the morphine
group (Fig. 2).
Significant differences were found in loss of appeti-
te between 1 and 2 measurement (tramadol) and 2 me-
asurement (morphine) and between 1 and 2, 2 and 3 me-
asurement (morphine).
Significant differences were not observed in pain
scale. Pain control was slightly better in the second and
third QL assessment in tramadol group (not significant).
In the first QL assessment results in both groups were
nearly the same.
Fig. 1. Global QL: interaction of the type of the treatment and time of
the QL measurement. Higher score means better QL
Fig. 2. Fatigue intensity: interaction of the type of the treatment and
the time of the QL assessment. Higher score means bigger intensity of
the symptom and worse QL
Explanations: Time of measurement: I – after first week of the treat-
ment, II – after third week of the treatment, III – after fifth week of
the treatment
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Effect of the group was observed in financial pro-
blems. Patients treated with morphine had more pro-
blems. Significant differences were observed between all
3 measurements in tramadol and morphine group.
Discussion
Beneficial, comparable analgesia was achieved during
treatment with tramadol and morphine expressed by the
significant decrease of pain intensity after first week of
therapy. The results indicate on high analgesic efficacy of
tramadol (drops, capsules) and morphine (water solu-
tion) in immediate release formulations. Similarly during
next four weeks of the treatment with controlled release
tramadol (Tramal Retard 100, 150, 200 mg tablets) and
morphine (MST Continus 10, 30, 60, 100 mg tablets and
M-eslon 10, 30, 60, 100 mg capsules) good analgesic effect
in both groups was maintained [1]. No difference in VAS,
verbal scale and patients' assessment of analgesia was no-
ted between both treated groups. These results indicate
for good analgesic efficacy of controlled release formula-
tions of tramadol and morphine.
There is an interesting trend in achieving better re-
sults with tramadol and slightly worse results with morphi-
ne (both in controlled release formulations) during the
course of the trial. This trend however didn't achieve sta-
tistical significance in any time.
Beneficial, comparable analgesic effects were achie-
ved in both groups in visceral pain (VAS <40 mm). In so-
matic pain from soft tissues after first week morphine
was more effective than tramadol (mean VAS 19 and 40
mm respectively) but this difference wasn't significant.
After 2nd, 3rd, 4th and 5th week results in both groups we-
re similar. In bone pain its intensity at the beginning was
stronger in the tramadol (VAS 90 mm) than in morphine
(72 mm – significant difference) group and this could ha-
ve contributed to slightly better results (not significant)
after 1st (41 vs 27 mm) and 2nd (47 vs 32 mm) week in
morphine group. In next measurements results in both
groups were similar.
In neuropathic pain after 1st week results were si-
gnificantly better in morphine than in tramadol group
(mean VAS 19 and 57 mm respectively). This trend was
maintained during all the trial period. Treatment with
tramadol in this type of pain was less effective (mean
VAS 49-60 mm). Morphine, especially in water solution
was more effective. It is understandable regarding less
sensitivity of this type of pain to opioid analgesic therapy.
Usually high doses of strong opioids with adiuvant analge-
sics are required to achieve effective pain relief.
In significant number of patients (63.6%) treated
with tramadol after completing the study period (mean ti-
me of therapy 48 days), it was necessary to substitute tra-
madol by morphine; in most patients (54.5%) the reason
for change was inadequate pain control, in the rest (9.1%)
the cause was severe dyspnoea. In the retrospective part
of this study (not depicted in this paper) substitution for
morphine was necessary in 35% (31% because of inade-
quate pain control) of patients treated with tramadol.
The mean time of tramadol treatment was 52 days. In
other studies the rates of change are different e. g. 70 %
[2]; in our own studies 33% [3] and 35% [4]. In
Grond's study [2] tramadol was safe and effective for me-
an time of 28 days – then it was changed for morphine. It
seems that treatment with tramadol can be effective, ho-
wever in 30-70 % of patients after different period of time
(mean 28-52 days) it is necessary to change the drug for
morphine or alternative strong opioid (e. g. transdermal
fentanyl). This is connected with increase in pain intensi-
ty caused by cancer progression. In a small proportion
of patients the reason for change is severe dyspnoea which
can be ameliorated by morphine; this reason is more fre-
quent in patients with primary or secondary lung or me-
diastinal tumours.
Majority of patients (80%) in both groups prefer-
red treatment with controlled release formulations. It is in
accordance with literature; this form of treatment is mo-
re convenient and improves compliance. Usually control-
led release formulations of tramadol [5] and morphine [6]
are administered every 12 hours; they are rarely taken
every 8 hours. Immediate release formulations of morphi-
ne and tramadol usually are taken every 4 hours [7].
Very good toleration of the treatment was noted
with immediate release formulations of tramadol and
morphine – no one patient stopped the treatment becau-
se of side effects. Good toleration was noted during treat-
ment with controlled release formulations of both drugs.
However 3 patients in tramadol group discontinued the-
rapy with Tramal Retard: one (500 mg/day) because of si-
de effects (sweating, anxiety, palpitations) returned
to tramadol in drops and side effects disappeared, one
(200 mg/day) because of inadequate analgesia returned to
the treatment with tramadol drops with better analgesia,
and the last one (400 mg/day) because of agitation, dysp-
noea and inadequate analgesia demanded morphine ad-
ministered subcutaneously (40 mg/day); after this change
improvement in pain control was noted.
In morphine group 2 patients discontinued the treat-
ment with M-eslon: one patient died during the study – he
received the dose 80 mg/day until death with satisfactory
analgesia, the second patient was treated with the same
dose of M-eslon – she experienced muscle tremor, anxie-
ty and inadequate analgesia – after 5 days she returned to
the treatment with morphine water solution (75 mg/day)
with better analgesia and disappearance of side effects.
These results indicate for slightly better toleration and
slightly better analgesia (it concerns mainly morphine)
with immediate release formulations. It is interesting that
analgesia with Tramal Retard improved (not significantly)
in comparison to drops or capsules. It is difficult to expla-
in this effect; maybe the non – opioid mode of action is
responsible or as suggested by some authors [8] lack of to-
lerance during tramadol treatment. During treatment
with morphine the best scores were achieved with water
solution; then analgesia was slightly worse (not signifi-
cant). It can be caused either by development of toleran-
ce for analgesia or by increase in pain intensity or by ob-
served in some patients unwillingness to escalate the do-
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se of morphine. These problems need clarification in con-
trolled, clinical trials.
Side effects observed during the study were usually
of mild or moderate intensity. In all explored side effects
their intensity was bigger in morphine group; however in
most cases they didn't reach statistical significance. Si-
gnificant difference in constipation intensity in favour of
tramadol (noted in retrospective study) was not observed
in this prospective trial. It can be explained by more fre-
quent gastrointestinal tumours in tramadol than in mor-
phine group (35% vs 20%) and more frequent use of laxa-
tives in the last group (70% vs 60%). 25% of patients on
morphine received 2, 3 or 4 laxatives while only 15% on
tramadol received 2 laxatives; the rest of patients in both
groups were treated with just one laxative.
Drowsiness was more intense in morphine group
(statistical significance in all 3 measurements); this is in
accordance with other authors data [8, 9]. Significant dif-
ferences were noted in difficulties in passing urine and
dizziness (on 21st day of the study) and in sweating (on 7th
day of the study) – all in favour of tramadol. The first
two symptoms are sometimes observed in patients tre-
ated with morphine; however dizziness and sweating are
typical side effects of tramadol. In patients treated with
morphine these symptoms are connected with cerebel-
lar ataxia, postural hypotension caused by alfa adrenergic
receptors blockade (dizziness) and autonomic nerve sys-
tem activation (sweating).
The increase of mean daily doses of tramadol was
17.24% and 11.03% after 3rd and 5th week of the treat-
ment respectively (in comparison to the dose after first
week of the treatment). This indicate that the biggest in-
crease of dose is noted during first week of the treat-
ment; the mean daily dose of tramadol after 5th week was
even less than after 3rd week (322 mg and 340 mg respec-
tively). These results seem indicating for good analgesia
possibly connected with monoamine re – uptake blockade
[10]. In our retrospective study [3] the increase of tra-
madol dose during 6 weeks of the therapy was 53% (from
260 mg after 1st week to 400 mg after 6th week) – this
bigger increase could be connected with higher daily do-
ses of tramadol (up to 900 mg) – in this study maximal do-
se was 600 mg/day.
The increase of mean daily doses of morphine was
much bigger – 24.1% and 49.4% after 3rd and 5th week
respectively (in comparison to the first week). Tawfik et al.
[9] noted 7% increase of tramadol dose and 41% increase
in morphine dose during 6 weeks of the treatment. Osipo-
va et al. [8] concluded that tramadol dose was stable and
MST Continus dose rose by 38.5% in this trial. Is the
cause of morphine dose increments tumour progression
or tolerance development for analgesia remains question
to be answered. However, in this present study the daily
doses of morphine during 5 weeks of the treatment did
not exceed 270 mg and it confirms that most of cancer pa-
tients demand only small or moderate doses of morphine
in order to achieve satisfactory pain control.
QL was assessed by QLQ C 30 questionnaire – QL
assessment tool commonly used in cancer patients [11].
QL results in functioning scales showed stable level of
physical functioning in both patients groups during the
trial period. There was a trend of significant improve-
ment in role functioning (work) observed between 2nd
and 3rd QL measurement. The opposite tendency of signi-
ficant decrease in cognitive, emotional and social functio-
ning in both groups was noted also between 2nd and 3rd
QL measurement. These results however were better in
morphine group, especially in emotional functioning (sta-
tistical significance). Worse results in functioning scales
could be caused by general deterioration observed in so-
me patients. However this has no confirmation in ECOG
and Karnofsky status changes; results of physical func-
tioning (improvement) are also in conflict with these data.
In global QL there was a tendency towards better
results in tramadol group since the 2nd measurement – it
achieved statistical significance in the 3rd assessment. This
can be explained by slightly better analgesia in tramadol
group after 5 weeks of therapy and also by less intensity of
drowsiness (all 3 side effects assessments) and fatigue
(3rd QL measurement) in patients treated with tramadol.
QL data in symptoms scales showed no significant
differences in nausea, vomiting and pain scale; also in
single items: dyspnoea, sleep disturbances, constipation
and diarrhoea. However intensity of all mentioned symp-
toms (with the exception of diarrhoea, nausea and vomi-
ting) were greater in morphine group.
Two factorial analysis of variance revealed statistical
difference in fatigue scale and loss of appetite scale. Fati-
gue intensity was greater in all 3 measurements in morphi-
ne group – in the third assessment it was statistically signi-
ficant. Loss of appetite intensity was significantly lower in
the 2nd measurement in morphine group.
In pain scale there was no significant difference be-
tween both groups. However pain scale in QLQ C 30 qu-
estionnaire is less accurate than VAS scale in the asses-
sment of pain intensity [12].
In the financial impact effect of the group of tre-
ated patients was noted; more financial problems were
in the morphine group; however this was caused by mo-
re difficult social situation and has no connection with
drug price (morphine and tramadol in both immediate
and controlled release formulations are free of charge
for cancer patients in Poland). The difference between
both groups was noted in all 3 measurements, but stati-
stical significance was achieved only in the 3rd QL asses-
sment.
There are no data comparing tramadol and small
doses of morphine in terms of QL assessment. Brema et
al. [13] compared in multicentre, randomised, long term
study controlled release tramadol with buprenorphine
using Spitzer Index QL; no difference between groups
have been found, however patients and physicians asses-
sed tramadol significantly higher.
In practice it is important to note that tramadol has
little influence on gastrointestinal motility and causes less
constipation in comparison to morphine. It can signifi-
cantly improve QL and reduce cost of the treatment con-
nected with the use of laxatives and enemas [14, 15]. Ano-
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ther advantage of tramadol could be less cognitive im-
pairment than morphine; it can be connected with less
drowsiness and less fatigue observed in this study. Ho-
wever this issue is not definitely explored and cognitive
impairment in patients with advanced cancer can be cau-
sed not only by opioid analgesics but also by many other
factors like metabolic disturbances e. g. liver or renal im-
pairment [16].
Equivalent analgesic doses of tramadol and morphi-
ne administered parenterally are about 10:1 [17]. Taking
into account higher bioavailability of tramadol (over 70%)
[18] than morphine (about 25-50%) [19] oral equivalent
doses of these analgesics should be about 5:1. The compa-
rison of mean daily doses of tramadol (297 mg) and mor-
phine (68.5 mg) from retrospective study revealed the
equivalent oral doses as 4.3:1. Similar results were achie-
ved in another study [4], equivalent tramadol and morphi-
ne daily doses were 321 mg and 77.50 mg respectively in-
dicating the ratio 4:1. Results in prospective study (mean
daily doses of tramadol and morphine were 322 mg and
123.5 mg respectively) indicate the ratio 3:1. However
taking into account that it was parallel study and over
63% of patients treated with tramadol demanded change
for morphine it can be assumed that the ratio is about
4:1. It is in accordance with the only one controlled, cross
– over study in cancer patients comparing tramadol and
morphine [20] where the calculation of equivalent tra-
madol and morphine dose was 4:1.
There is no clear rule whether in patients with pain
of moderate and severe intensity treatment should be
started from weak or strong opioids [21]. It seems reaso-
nable that in moderate pain intensity (VAS 30-54 mm)
tramadol should be tried. In patients with severe pain
(VAS >54 mm) oral morphine (EAPC recommenda-
tions) [22] or transdermal fentanyl are used but tramadol
can be alternative for small doses of morphine in older
and in patients with gastrointestinal disturbances. It is
supported by results of Wilder – Smith et al. [20], Osipo-
va et al. [8, 23], Rodrigues and Pereira [24] and own expe-
rience [4] also in this study. Further research is required
focusing on pain control, side effects and particularly QL
during long term treatment of cancer pain with tramadol
in controlled clinical trials.
Introducing controlled release formulations of mor-
phine [25,26] and tramadol [27] in Poland caused signifi-
cant improvement in cancer pain treatment and patients'
QL. Further progress is connected with the introduction
of transdermal fentanyl in patches [28] and methadone
[29] in solution which allowed for opioid rotation [30] if
the treatment with morphine is unsuccessful.
Conclusions
1. The use of tramadol and equianalgesic doses of mor-
phine not exceeding 270 mg daily, by the oral route, in
immediate and controlled release preparations, allo-
wed to achieve effective analgesia in patients with dif-
ferent types of cancer pain with moderate and strong
intensity.
2. Tramadol is less effective in the treatment of neuropa-
thic pain; strong opioids with appropriate adiuvant
analgesics are recommended in this type of pain.
3. Immediate and controlled release preparations of tra-
madol and morphine administered orally can be safe-
ly used at home.
4. Most (80%) patients treated with tramadol and mor-
phine preferred controlled release preparations.
5. Administration of tramadol is connected with better
global QL and less fatigue after 5 weeks of the treat-
ment.
6. Equianalgesic doses of morphine and tramadol admi-
nistered orally are 1:4.
7. Tramadol should be administered in patients with mo-
derate pain intensity (VAS 30-54 mm) and morphine is
indicated in patients with strong and very strong pain
intensity (VAS >54 mm).
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